APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

NCT06634394 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG: APVO436
DRUG: Venetoclax
DRUG: Azacitidine

Sponsor

Aptevo Therapeutics